HINODE study
- Conditions
- Congenital haemophilia A
- Registration Number
- JPRN-jRCT1031230264
- Lead Sponsor
- ogami Keiji
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion criteria;
1)Patientss for whom consent to participate in the study has been obtained from proxy consenters by means of written informed consent
2) Confirmed diagnosis with Congenital haemophilia A at enrollment.
3)Patients selected for the treatment with emicizumab as the most appropriate medical treatment (those who planned to receive emicizumab treatment in the selection of the treatment between physicians and patients) and who are receiving or scheduled to receive emicizumab according to the current electronic package insert dosage and administration.
4)Patients who have reached or are likely to reach the maintenance phase* of emicizumab at less than 12 months of age and are able to obtain blood samples in the maintenance phase* of less than 12 months of age.
*The maintenance phase in this study refers to the fifth and subsequent doses of emicizumab.
Exclusion criteria;
1)Patients with inherited or acquired bleeding disorders other than haemophilia A.
2)Patients to be inappropriate to enter this study for some other reason judged by the investigators.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method